The Zhitong Finance App learned that UBS published a report lowering the target price of Ali Health (00241.HK) from HK$3.1 to HK$2.8 to maintain the “sale” rating; the new target price is based on 17 times adjusted profit per share for the 2028 fiscal year. Previously, it was 19 times, slightly lower than the Internet medical industry average, to reflect the company's weak profit growth prospects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.